EGFR and ovarian cancer: Herein, we have described the proof-of-concept for targeted eradication of the ovarian cancer cells in five stages: (I) anti-EGFRvIII or anti-EGFR antibody guided delivery of the vectors carrying the transgenes for the human recombinant DNASE1, DNASE1L3, DNASE2, DFFB; (II) expressing these transgenes under the control of EGFR promoter; (III) guiding the transgenes’ expression products into the nuclei of the ovarian cancer cells; (IV) complete degradation of the ovarian cancer cells’ genomic DNA; (V) death of the transduced ovarian cancer cells.